Skin Cancer

In basal cell carcinoma, the most common type of skin cancer accounting for 80% of all non-melanoma skin cancers, one of the leading options for cases that fall into this category is targeted treatment with Hedgehog pathway inhibitors.

Although Merkel cell carcinoma can develop undetected or at a metastasized site, it usually first appears as a painless lump or nodule on an area of the skin that has been exposed to the sun.

To date, it is unknown what impact potential response-adapted treatment strategies for advanced melanoma may have economically.

New research suggests new pharmacological therapies are associated with a decrease in melanoma-related deaths.

Precision medicine may help improve the diagnosis and management of this aggressive skin cancer.

At the 2022 Fall Clinical Dermatology Conference, a dermatologist shares results of using cemiplimab-rwlc (Libtayo) for basal and squamous cell carcinoma.

At a session at the 2022 Fall Clinical Dermatology Conference, 2 clinicians discuss some of the top testing methods for skin cancer.

At the Melanoma Update of the Annual ASDS Meeting, Tyler Hollmig, MD, looked at complex clinical scenarios when treating melanoma and the continued challenges dermatologists face.

Kimberly Ken, MD, assistant professor of dermatology at Penn State University, discussed crucial methods for advanced melanoma management.

Authors of an oral abstract at the 2022 ASDS Annual Meeting presented their findings on the demographics of who requests total body skin exams to screen for skin cancer.

Sherrif F. Ibrahim, MD, PhD, and Vishal Patel, MD, FAAD, FACMS, provide initial impressions of the case and discuss the use of immune checkpoint inhibitors.

Sherrif F. Ibrahim, MD, PhD, presents the case of a 49-year-old White woman with neglected large basal cell carcinoma.

Expert dermatologists discuss future directions for the management of basal cell carcinoma.

Sherrif F. Ibrahim, MD, PhD, and Vishal Patel, MD, FAAD, FACMS, discuss the impact of immune checkpoint inhibitors used in BCC.

Experts in dermatology discuss the treatment landscape for BCC.

Precision medicine may help improve the diagnosis and management of melanoma.

Bristol Myers Squibb’s nivolumab shows potential for treatment in earlier stages of melanoma.

Drs Sherrif F. Ibrahim and Vishal Patel discuss the importance of a multidisciplinary team in the treatment of BCC as well as best practices for preventing advanced BCC.

Sherrif F. Ibrahim, MD, PhD, and Vishal Patel, MD, FAAD, FACMS, provide an overview of BCC and discuss disease burden.

At a poster session at the Skin of Color Update meeting in New York City, investigators looked at skin cancer education and prevention among patients with skin of color.

Susan Taylor, MD, FAAD, discusses how an individual can select a sunscreen as well as barriers to using them.

Dr Susan Taylor, an expert dermatologist, discusses how to increase awareness and avoid misconceptions for individuals using sunscreens.

Susan Taylor, MD, FAAD, discusses how to select a sunscreen based on different patient characteristics.

Expert dermatologist, Susan Taylor, MD, FAAD, discusses available sunscreen options to patients.

Susan Taylor, MD, FAAD, discusses FDA regulations for sunscreens.